Anti-infective therapy using species-specific activators of Staphylococcus aureus ClpP

Area of Science:

• Microbiology
• Drug Discovery
• Structural Biology

Background:

• The rise of antibiotic-resistant bacteria, like methicillin-resistant Staphylococcus aureus (MRSA), necessitates novel therapeutic strategies.
• Bacterial ClpP protease, a conserved ATP-dependent protease, presents a potential target for antibiotic development.
• Developing selective ClpP activators that avoid human ClpP interference is crucial for therapeutic safety.

Purpose of the Study:

• To identify selective activators of Staphylococcus aureus ClpP using structure-based design.
• To investigate the structural basis for selectivity between bacterial and human ClpP.

Main Methods:

• Structure-based drug design was employed to identify novel ClpP activators.
• The selectivity of identified compounds was assessed against Staphylococcus aureus and Homo sapiens ClpP.
• Antibiotic efficacy was evaluated in vitro against multidrug-resistant strains and in vivo using zebrafish and murine infection models.

Main Results:

• The study identified (R)- and (S)-ZG197 as highly selective activators of Staphylococcus aureus ClpP.
• Structural analysis revealed key differences in Homo sapiens ClpP, including W146 and its C-terminal motif, contributing to selective binding.
• The identified activators demonstrated broad-spectrum activity against resistant staphylococcal strains and significant efficacy in preclinical infection models.

Conclusions:

• Species-specific activators of Staphylococcus aureus ClpP are viable therapeutic candidates.
• Targeting bacterial ClpP offers a promising avenue for combating staphylococcal infections, including those caused by resistant strains.
• Structure-based design is an effective approach for developing selective antibacterial agents.